Table 2.
Clinical fractures during teriparatide treatment (0–24 months) for the active treatment cohort
| Time interval (months) | N a | Number of fractures per 10,000 patient years | Total number of fractures | Patients with ≥1 fracture, n (%)b | Odds of fracture (95 % CI)c | Odds ratioc,d (95 % CI) | p valued |
|---|---|---|---|---|---|---|---|
| 0–6 | 1454 | 670 | 48 | 44 (3.0 %) | 0.017 (0.009–0.031) | – | – |
| >6–12 | 1384 | 461 | 31 | 28 (2.0 %) | 0.011 (0.006–0.021) | 0.66 (0.42–1.04) | 0.075 |
| >12–18 | 1295 | 401 | 25 | 22 (1.7 %) | 0.009 (0.005–0.019) | 0.55 (0.33–0.92) | 0.022 |
| >18–24 | 1087 | 436 | 18 | 17 (1.6 %) | 0.009 (0.004–0.018) | 0.51 (0.29–0.90) | 0.021 |
| Totale | 1454 | 122 | 103 (7.1 %) |
CI confidence interval
a N = all patients with information regarding fractures within the time window
bAs some patients experienced a fracture in more than one time interval, the total was not the sum of patients with a fracture in each interval
cAdjusted model by gender, age, prior bisphosphonate/denosumab use, and history of vertebral or non-vertebral fracture in the 12 months before starting teriparatide
dCompared with 0- to 6-month interval
eAll fractures from treatment start to end of treatment within the 24 months are included